Year: 2022
Type: article
Abstract: Direct injection of therapies into tumors has emerged as an administration route capable of achieving high local drug exposure and strong anti-tumor response. A diverse array of immune agonists ranging in size and target are under development as local immunotherapies. However, due to the relatively recent adoption of intratumoral administration, the pharmacokinetics of locally-injected biologics remains poorly defined, limiting rational design of tumor-localized immunotherapies. Here we define a pharmacokinetic framework for biologics injected intratumorally that can predict tumor exposure and effectiveness. We find empirically and computationally that extending the tumor exposure of locally-injected interleukin-2 by increasing molecular size and/or improving matrix-targeting affinity improves therapeutic efficacy in mice. By tracking the distribution of intratumorally-injected proteins using positron emission tomography, we observe size-dependent enhancement in tumor exposure occurs by slowing the rate of diffusive escape from the tumor and by increasing partitioning to an apparent viscous region of the tumor. In elucidating how molecular weight and matrix binding interplay to determine tumor exposure, our model can aid in the design of intratumoral therapies to exert maximal therapeutic effect.
Source: Nature Communications
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,890
Funders: National Science Foundation, U.S. Department of Defense, U.S. Department of Health and Human Services, Paul and Daisy Soros Fellowships for New Americans, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, National Institutes of Health, Directorate for Education and Human Resources, National Cancer Institute, National Institute of General Medical Sciences, Division of Graduate Education, Division of Cancer Epidemiology and Genetics, National Cancer Institute
Awards: G1151953971, G1350115407, EXTRACELLULAR MATRIX BIOMARKERS FOR DIAGNOSIS, PROGNOSIS, IMAGING AND TARGETING, G2360436881, G4119534169, G418671524, G4757224750, G4774430914, G504497627, G5108852245, G5735053113, G5850682332, G5898795573, Localizing Immunotherapy to Improve Therapeutic Index, G7888124300, Cancer Center Support (Core) Grant, TRAINING GRANT IN MOLECUCLAR IMAGING RESEARCH AND CANCER SYSTEMS ANALYSIS, G941982536, G950397266
OpenAlex ID: W4205129096
